Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Drug Resistance

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 65 articles: HTML format Text format

Single Articles

November 2011
1. SHIN JW , Jung SW, Park BR, Kim CJ, et al
   HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
   Antivir Ther. 2011 Nov 2. doi: 10.3851/IMP1945.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
2. KOUANFACK C , Aghokeng AF, Mondain AM, Bourgeois A, et al
   Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
   Antivir Ther. 2011 Sep 23. doi: 10.3851/IMP1911.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2011
3. MASCOLINI M , Mellors JW, Richman DD, Boucher CA, et al
   HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies.
   Antivir Ther. 2011;16:263-86.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. BOYD SD , Maldarelli F, Sereti I, Ouedraogo GL, et al
   Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
   Antivir Ther. 2011;16:257-61.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. YOUNG B , Fransen S, Greenberg KS, Thomas A, et al
   Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
   Antivir Ther. 2011;16:253-6.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. HURT CB
   Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.
   Antivir Ther. 2011;16:137-40.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. HAMERS RL , Wensing AM, Back NK, Arcilla MS, et al
   Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
   Antivir Ther. 2011;16:115-8.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. PILGER D , Hauser A, Kuecherer C, Mugenyi K, et al
   Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
   Antivir Ther. 2011;16:109-13.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. LATHOUWERS E , De Meyer S, Dierynck I, Van de Casteele T, et al
   Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
   Antivir Ther. 2011;16:99-108.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. HAN KH , Hong SP, Choi SH, Shin SK, et al
    Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
    Antivir Ther. 2011;16:77-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. PULIDO F , Arribas JR, Hill A, Van Delft Y, et al
    Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Antivir Ther. 2011;16:59-65.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. HOMS M , Jardi R, Buti M, Schaper M, et al
    HBV core region variability: effect of antiviral treatments on main epitopic regions.
    Antivir Ther. 2011;16:37-49.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. BUCKTON AJ , Harris RJ, Pillay D, Cane PA, et al
    HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis.
    Antivir Ther. 2011;16:9-16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. CHARPENTIER C , Bellecave P, Cisse M, Mamadou S, et al
    High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Antivir Ther. 2011;16:429-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. TREVINO A , de Mendoza C, Parra P, Rodriguez C, et al
    Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
    Antivir Ther. 2011;16:413-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. SCHAPIRO JM , Boucher CA, Kuritzkes DR, van de Vijver DA, et al
    Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Antivir Ther. 2011;16:395-404.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. GARCIA F , Alvarez M, Fox Z, Garcia-Diaz A, et al
    Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Antivir Ther. 2011;16:373-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. VAN DE VEN AA , Douma JW, Rademaker C, van Loon AM, et al
    Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
    Antivir Ther. 2011;16:611-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. RAMEIX-WELTI MA , Munier S, Le Gal S, Cuvelier F, et al
    Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
    Antivir Ther. 2011;16:597-603.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. TUMA P , Pineda JA, Labarga P, Vidal F, et al
    HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
    Antivir Ther. 2011;16:585-589.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. DE LUCA A , Di Giambenedetto S, Maserati R, Gianotti N, et al
    Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    Antivir Ther. 2011;16:489-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. CHARPENTIER C , Larrouy L, Matheron S, Damond F, et al
    Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Antivir Ther. 2011;16:937-940.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. CORNELISSEN M , Back NK, Burger DM, Blom P, et al
    Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
    Antivir Ther. 2011;16:931-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. KOZAL MJ , Chiarella J, St John EP, Moreno EA, et al
    Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Antivir Ther. 2011;16:925-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. JI H , Li Y, Graham M, Liang BB, et al
    Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance.
    Antivir Ther. 2011;16:871-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. FOX ZV , Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, et al
    Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
    Antivir Ther. 2011;16:781-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. HAMELIN ME , Baz M, Bouhy X, Beaulieu E, et al
    Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
    Antivir Ther. 2011;16:775-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. GATHE J , Andrade-Villanueva J, Santiago S, Horban A, et al
    Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
    Antivir Ther. 2011;16:759-69.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. MCKINNON JE , Delgado R, Pulido F, Shao W, et al
    Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    Antivir Ther. 2011;16:725-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. SHEAFFER AK , Lee MS, Hernandez D, Chaniewski S, et al
    Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Antivir Ther. 2011;16:705-18.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
31. MOLTO J , Valle M, Santos JR, Mothe B, et al
    Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Antivir Ther. 2010;15:219-25.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. PRICE H , Asboe D, Pozniak A, Gazzard B, et al
    Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    Antivir Ther. 2010;15:203-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. LUI YY , Tsoi KK, Wong VW, Kao JH, et al
    Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
    Antivir Ther. 2010;15:145-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. ROCKSTROH JK , Gatell J, Landman R, Antinori A, et al
    Management of late-presenting patients with HIV infection.
    Antivir Ther. 2010;15 Suppl 1:25-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. TENNEY DJ
    Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. DURANTEL D
    Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. KUIKEN C
    Designing a low-cost drug resistance database for viral hepatitis.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. KHUDYAKOV Y
    Coevolution and HBV drug resistance.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. LACOMBE K , Boyd A, Gozlan J, Lavocat F, et al
    Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. THIO CL
    Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. YEH CT
    Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. LOCARNINI SA , Yuen L
    Molecular genesis of drug-resistant and vaccine-escape HBV mutants.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. TEO CG , Locarnini SA
    Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
    Antivir Ther. 2010;15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. BARNAS D , Koontz D, Bazmi H, Bixby C, et al
    Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Antivir Ther. 2010;15:437-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. CUNYAT F , Ruiz L, Marfil S, Puig T, et al
    Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Antivir Ther. 2010;15:431-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. AULICINO PC , Rocco CA, Mecikovsky D, Bologna R, et al
    HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Antivir Ther. 2010;15:641-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. MARTIN M , Azzi A, Lin SX, Boivin G, et al
    Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
    Antivir Ther. 2010;15:579-86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. VALINOTTO LE , Diez RA, Barrero PR, Farias JA, et al
    Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus.
    Antivir Ther. 2010;15:923-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. VERHEYEN J , Schweitzer F, Harrer EG, Knops E, et al
    Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates.
    Antivir Ther. 2010;15:907-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. LAN Y , Zhang Y, Dong L, Wang D, et al
    A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009.
    Antivir Ther. 2010;15:853-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. ORTQVIST P , Vema A, Ehrenberg AE, Dahl G, et al
    Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
    Antivir Ther. 2010;15:841-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. TOWNER WJ , Cassetti I, Domingo P, Nijs S, et al
    Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
    Antivir Ther. 2010;15:803-16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. OTTMANN M , Duchamp MB, Casalegno JS, Frobert E, et al
    Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.
    Antivir Ther. 2010;15:721-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. RUIZ-CARRASCOSO G , Casas I, Pozo F, Gonzalez-Vincent M, et al
    Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant.
    Antivir Ther. 2010;15:1059-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. JOHANNESSEN A , Holberg-Petersen M, Lovgaarden G, Naman E, et al
    HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania.
    Antivir Ther. 2010;15:1003-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. GHOSN J , Carosi G, Moreno S, Pokrovsky V, et al
    Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
    Antivir Ther. 2010;15:993-1002.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. CHILTON DN , Castro H, Lattimore S, Harrison LJ, et al
    HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.
    Antivir Ther. 2010;15:985-991.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. LLIBRE JM
    Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.
    Antivir Ther. 2010;15:959-61.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. BRUNETTO MR , Lok AS
    New approaches to optimize treatment responses in chronic hepatitis B.
    Antivir Ther. 2010;15 Suppl 3:61-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. LOCARNINI S , Zoulim F
    Molecular genetics of HBV infection.
    Antivir Ther. 2010;15 Suppl 3:3-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. LIU Y , Wang C, Zhong Y, Chen L, et al
    Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Antivir Ther. 2010;15:1185-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. YANG JX , Liu BM, Li XG, Yan CH, et al
    Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Antivir Ther. 2010;15:1171-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. DIERYNCK I , De Meyer S, Lathouwers E, Vanden Abeele C, et al
    In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Antivir Ther. 2010;15:1161-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. GUBAREVA LV , Trujillo AA, Okomo-Adhiambo M, Mishin VP, et al
    Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Antivir Ther. 2010;15:1151-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. EIDE K , Moerdyk-Schauwecker M, Stein DA, Bildfell R, et al
    Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
    Antivir Ther. 2010;15:1141-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: